Biggest News Aggregation in the World
📰 Discovery Engine News

Page 2 - Discovery Engine News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Discovery Engine. Real-time updates on events, politics, business and more.

DIY Guide: Creating a Stylish Girl's Bed Headboard on Pinterest

Have you ever seen your daughter’s bedroom and wondered what was missing? Perhaps it’s the absence of a charming headboard that would transform her space into a dreamy haven. It would be very exciting for her if she found a bed that fit snugly for a princess when she woke up. How did you make […]
Focal Points Personal Style Room Aesthetics Discovery Engine Design Concepts User Showcases

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide ... | Region

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring
John Houston Jeff Boyle Daniel Petrylak Kirsten Owens European Society For Medical Oncology Congress Company Phase

Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC -October 22, 2023 at 07:01 am EDT

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors...
Kirsten Owens Daniel Petrylak John Houston Jeff Boyle Exchange Commission Arvinas Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023
Jeff Boyle Kirsten Owens Pfizer Inc Arvinas Inc European Society For Medical Oncology Arvinas Communications

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential trea...
Jeff Boyle Daniel Petrylak European Society For Medical Oncology Arvinas Inc Exchange Commission Medical Oncology
Source: yahoo.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science